Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD46 Double Nickase Plasmid (h): sc-400968-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD46 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD46 Double Nickase Plasmid (h) and CD46 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD46. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD46 Antibody (C-10): sc-166159
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD46 Double Nickase Plasmid (h) | sc-400968-NIC | 20 µg | $410.00 | |||
CD46 Double Nickase Plasmid (h2) | sc-400968-NIC-2 | 20 µg | $410.00 |
CD46 (membrane cofactor protein) is a ubiquitously expressed complement regulatory glycoprotein that protects host cells from autologous complement attack by serving as a cofactor for factor I–mediated cleavage of C3b and C4b, thereby dampening classical and alternative pathway amplification. Through its roles at the cell surface, CD46 shapes innate immune signaling, inflammatory tone, and cell–cell interactions, and is linked to processes such as leukocyte activation and epithelial barrier biology. Altered CD46 function or expression has been associated with complement-driven pathophysiology, including atypical hemolytic uremic syndrome and other immune-mediated inflammatory conditions. CD46 also serves as a receptor for select pathogens, making it relevant for studies of host–microbe interactions and immune evasion.
CD46 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD46 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD46. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD46 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD46-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.